Postprandial serum @entity2690 to plasma @entity413 ratio as a predictor of subsequent insulin treatment in @entity1 with @entity164 2 XXXX .

@entity1 @entity6 @entity2690 @entity164 @entity13324 @entity413
@entity164 2 @entity6 is a progressive disease and most @entity1 with @entity164 2 @entity6 eventually need insulin therapy. The objective of this study was to clarify @entity2690 immunoreactivity ( @entity13324 ), a marker of beta cell function, as a predictor of requirement for insulin therapy. We conducted a retrospective study of 579 consecutive subjects with @entity164 2 @entity6 who were admitted to our hospital from 2000 to 2007 and were able to be followed up for at least 6 months after discharge. Fasting and postprandial serum @entity13324 and urinary @entity13324 levels had been measured during admission. Information about insulin therapy at the last visit was obtained from medical records. At the last visit, 364 subjects (62.9%) were treated with insulin. Mean interval between discharge and the last visit was 4.5    2.3 years. Serum and urine @entity13324 levels at baseline were significantly associated with insulin treatment at the last visit (P<0.001 for all). Among @entity13324 values, postprandial serum @entity13324 to plasma @entity413 ratio ( @entity13324 index) showed the greatest area under the receiver operating characteristic (ROC) curve for insulin therapy. Multivariate logistic regression analysis evaluating the effect of postprandial @entity13324 index adjusted for other confounders showed consistent results with unadjusted results. In conclusion, beta cell dysfunction is significantly correlated with future insulin therapy in @entity1 with @entity164 2 @entity6 . Our study indicates that among @entity13324 measurements, postprandial @entity13324 index is the best predictive marker for future insulin therapy.
